Protagenic Therapeutics, Inc. (PTIX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は New York City, NY, アメリカ. 現CEOは Garo H. Armen.
PTIX を有する IPO日 2021-04-27, 1 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $1.08M.
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
